Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Lung Cancer treatment details. Chemotherapy. University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States



Survival: 9.5 months
   
Toxicity Grade: 4
   
Treatments: Chemotherapy
   
Drugs:
Country: United States
   
City/State/Province: Pittsburgh, PA
   
Hospital: University of Pittsburgh Cancer Institute
   
Journal: Link
   
Date: 9/2013

Description:
Patients:
This study involved squamous cell non-small-cell lung cancer patients who were divided into two separate treatment groups. Group A consisted of 229 patients with a median age of 59 years, 90% of whom were male. Group B had of 221 patients with a median age of 59 years, 90% of whom were male.

Treatment:
Patients in group A were treated with the chemotherapy agents nab-paclitaxel and carboplatin.
Patients in group B were treated with the chemotherapy agents paclitaxel (solvent-based) and carboplatin.

Toxicities:
The most severe toxicities in group A were of grade 4 and included anemia and thrombocytopenia. Grade 3 fatigue and nerve toxicity were also reported.

The most severe toxicities in group B were of grade 4 and included neutropenia and nerve toxicity.

Results:
The median overall survival times for groups A and B were 10.7 and 9.5 months, respectively.

Support:
This study was supported by Celegene, makers of Abraxane (brand name for nab-paclitaxel).

Correspondence: Dr. Mark A. Socinski; email: socinskima@upmc.edu

E-mail to a Friend Email Physician More Information